INSM

INSM

USD

Insmed Incorporated Common Stock

$182.770-2.510 (-1.355%)

Precio en Tiempo Real

Healthcare
Biotecnología
Estados Unidos

Gráfico de Precios

Loading Chart...

Métricas Clave

Métricas de Mercado
Fundamentos de la Empresa
Estadísticas de Negociación

Métricas de Mercado

Apertura

$185.280

Máximo

$187.880

Mínimo

$182.580

Volumen

1.57M

Fundamentos de la Empresa

Capitalización de Mercado

39.0B

Industria

Biotecnología

País

United States

Estadísticas de Negociación

Volumen Promedio

2.46M

Bolsa

NMS

Moneda

USD

Rango de 52 Semanas

Mínimo $60.4Actual $182.770Máximo $197.08

Noticias Relacionadas

Analyst Upgrades

Wells Fargo Maintains Overweight on Insmed, Raises Price Target to $217

Wells Fargo analyst Tiago Fauth maintains Insmed with a Overweight and raises the price target from $171 to $217.

Ver más
Wells Fargo Maintains Overweight on Insmed, Raises Price Target to $217
Analyst Upgrades

Goldman Sachs Maintains Buy on Insmed, Raises Price Target to $225

Goldman Sachs analyst Andrea Tan maintains Insmed with a Buy and raises the price target from $196 to $225.

Ver más
Goldman Sachs Maintains Buy on Insmed, Raises Price Target to $225
Analyst Upgrades

UBS Maintains Buy on Insmed, Raises Price Target to $223

UBS analyst Trung Huynh maintains Insmed with a Buy and raises the price target from $194 to $223.

Ver más
UBS Maintains Buy on Insmed, Raises Price Target to $223
Analyst Upgrades

RBC Capital Maintains Outperform on Insmed, Raises Price Target to $215

RBC Capital analyst Leonid Timashev maintains Insmed with a Outperform and raises the price target from $139 to $215.

Ver más
RBC Capital Maintains Outperform on Insmed, Raises Price Target to $215
Analyst Upgrades

B of A Securities Maintains Buy on Insmed, Raises Price Target to $187

B of A Securities analyst Jason Zemansky maintains Insmed with a Buy and raises the price target from $142 to $187.

Ver más
B of A Securities Maintains Buy on Insmed, Raises Price Target to $187
Analyst Upgrades

UBS Maintains Buy on Insmed, Raises Price Target to $194

UBS analyst Trung Huynh maintains Insmed with a Buy and raises the price target from $140 to $194.

Mantente Actualizado

Configura alertas de precio, recibe actualizaciones de análisis de IA y noticias de mercado en tiempo real.